BioSpace News Archive

Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca

Lightnix Inc. has decided to participate as a partner company in “Innovation Infusion Japan”, an initiative sponsored by AstraZeneca K.K. i2.JP is a new initiative that promotes open innovations in the healthcare field.

December 25, 2022
·
1 min read
Drug Development

Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company’s Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19 vaccine ReCOV in the Philippines.

December 25, 2022
·
6 min read
Policy

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced that the companies have not received an action letter from the U.S. Food and Drug Administration regarding the Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma by the Prescription Drug User Fee Action date of December 23, 2022.

December 25, 2022
·
8 min read